CT 1119
Alternative Names: CT-1119Latest Information Update: 10 Apr 2024
At a glance
- Originator University of Pennsylvania
- Developer Carisma Therapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Macrophage replacements; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Solid tumours
Most Recent Events
- 31 Dec 2023 Suspended - Preclinical for Solid tumours in USA (Parenteral)
- 09 Nov 2023 Carisma Therapeutics announces intention to submit Investigational New Drug (IND) application for Solid tumour in December 2025
- 10 Aug 2023 Carisma Therapeutics plans to select a next-generation candidate for CT 1119 in the first half of 2024